Sensus Healthcare wins another indication for melanoma treatment

May 30, 2013 by Sony Salzman

The FDA says Sensus Healthcare's non-surgical skin cancer treatment can be used to treat keloid scars.

Sensus Healthcare wins another indication for melanoma treatment

The FDA granted another indication for Sensus Healthcare's topical skin cancer device, for treating keloid scars.

The Danbury, Conn.-based medical device company said its SRT-100 "superficial radiotherapy" product has already won 510(k) clearance from the federal watchdog for treating some skin cancers.

Sensus touts the device's SharpBeam technology as targeting only lesion areas to spare adjacent healthy tissue. The SRT-100 is cleared for treating non-melanoma skin cancers such as basal cell and squamous cell carcinomas.

Sign up to get our free newsletters delivered right to your inbox.

"It is very fortunate that the FDA has approved the Sensus SRT-100, the first computerized, state of the art in office SRT device, for the treatment of recurrent keloid scars. Dermatologists now have a safe, effective in office modality available to offer our keloid patients," said Mark Nestor, a doctor with the Center for Cosmetic Enhancement, said in a company statement.